Dr. Swain is currently the executive director of the Singapore Institute for Clinical Sciences within the Singapore Agency for Science, Technology, and Research (A*STAR), and the Lien Ying Chow Professor of Medicine at the National University of Singapore. Before going to Singapore, she was the dean for translational medicine at the University of California, San Diego, where she continues to maintain an appointment as an adjunct professor of medicine. Dr. Swain previously served as chair of the Department of Medicine at Stanford University, and on the medical faculties of the University of Pennsylvania and Duke University. Dr. Swain is widely known in the field of molecular cardiology, and pioneered the use of transgenic animals to understand the genetic basis of cardiovascular development and disease.
"The nature of Lexicon's drug discovery engine offers unprecedented opportunities to bring breakthrough drugs to patients in need," said Dr. Swain. "The pipeline under development already contains drug candidates with the potential to have a significant impact in medicine. It is indeed an exciting time to join the company's board as it translates its discoveries into drug development. I have great expectations for the future of Lexicon."
Dr. Swain serves as a director of the Burroughs Wellcome Fund, on the
scientific advisory board of the Doris Duke Charitable Foundation, and as a
director or member of the scientific advisory boards for a number of
privately-held biomedical technology companies. Dr. Swain is a member of
the Association of American Physicians, the American Society for Clini
|SOURCE Lexicon Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved